Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2704-2712

  Mitsiades, Nicholas ^a   Poulaki, Vassiliki ^a   Mitsiades, Constantine ^a   Tsokos, Maria ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 8 INHIBITORY PROTEIN; CASPASE 9; CASPASE INHIBITOR; CELL RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; EWING SARCOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL MEMBRANE; CYCLOHEXIMIDE; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; MEMBRANE GLYCOPROTEINS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SARCOMA, EWING'S; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035866804     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Apoptosis signaling by death receptors
2. The receptor for the cytotoxic ligand TRAIL
3. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
4. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
5. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
6. Characterization of two receptors for TRAIL
7. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
8. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
9. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
10. Expression of Fas ligand by human cytotrophoblasts: Implications in placentation and fetal survival
11. Fas ligand-induced apoptosis as a mechanism of immune privilege
12. A role for CD95 ligand in preventing graft rejection
13. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
14. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors
15. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase
16. Lethal effect of the anti-Fas antibody in mice
17. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors
18. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
19. The DNA of Annexin V-binding apoptotic cells is highly fragmented
20. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells
21. Detection of apoptotic cells from peripheral blood of HIV-infected individuals using a novel monoclonal antibody
22. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
23. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
24. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis
25. Fas-mediated apoptosis in peripheral primitive neuroectodermal tumor (PNET)/Ewing's sarcoma (ES)
26. TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation
27. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
28. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
29. Functional analysis of TRAIL receptors using monoclonal antibodies
30. Expression of TRAIL and its receptors in human brain tumors
31. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway
32. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
33. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
34. Inhibition of death receptor signals by cellular FLIP
35. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis
36. Identification and characterization of a new member of the TNF family that induces apoptosis
37. Safety and antitumor activity of recombinant soluble Apo2 ligand
38. Recombinant human TNF-related apoptosis inducing ligand (hu TRAIL) induces apoptosis of human multiple myeloma (MM) cells
39. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
40. APO2 ligand: A novel lethal weapon against malignant glioma?
41. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours
42. P53 mutations in Ewing's sarcoma, primitive neuroectodermal tumors and neuroblastoma
43. Preclinical experimental therapeutic approaches in soft tissue sarcoma
44. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
45. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α
46. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
47. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase
48. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
49. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
50. Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion
51. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
52. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance
53. Molecular determinants of response to TRAIL in killing of normal and cancer cells
54. Rare loss-of-function mutation of a death receptor gene in head and neck cancer
55. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas
56. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
57. Temperature-sensitive differential affinity of TRAIL for its receptors DR5 is the highest affinity receptor
58. KILLER/DR5 is a DNA damage/inducible p53-regulated death receptor gene
59. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
60. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
61. A novel receptor for Apo2L/TRAIL contains a truncated death domain
62. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
63. Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia
64. Biological and clinical effects of intravenous tumor necrosis factor-α administered three times weekly
65. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A Phase I and pharmacologic study